期刊
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
卷 103, 期 16, 页码 1222-1226出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djr246
关键词
-
类别
资金
- NCI NIH HHS [P30 CA021765] Funding Source: Medline
It is becoming increasingly evident that cancers are dependent on a number of altered molecular pathways and can develop diverse mechanisms of resistance to therapy with single agents. Therefore, combination regimens may provide the best hope for effective therapies with durable effects. Despite preclinical data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers. A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据